Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD

Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD

Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD

Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD

Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD

Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD

Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD

AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD

AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD

Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD

Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD

MajesTEC-3 Late-Breaking Trial Results | Luciano Costa, MD

MajesTEC-3 Late-Breaking Trial Results | Luciano Costa, MD

Promising Therapy for Hard-to-treat DLBCL: Epcoritamab + GemOx #DLBCL | Joshua Brody, MD

Promising Therapy for Hard-to-treat DLBCL: Epcoritamab + GemOx #DLBCL | Joshua Brody, MD

Improving Outcomes in FLT3-mutant AML: Crenolanib + Chemo | Thomas Cluzeau, MD, PhD

Improving Outcomes in FLT3-mutant AML: Crenolanib + Chemo | Thomas Cluzeau, MD, PhD

Highlights of Relapsed/Refractory Multiple Myeloma | Mohamad Mohty, MD, PhD

Highlights of Relapsed/Refractory Multiple Myeloma | Mohamad Mohty, MD, PhD

Highlights of Newly Diagnosed Multitple Myeloma | Mohamad Mohty, MD, PhD

Highlights of Newly Diagnosed Multitple Myeloma | Mohamad Mohty, MD, PhD